Eli Lilly to Acquire Centessa Pharmaceuticals for $38 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Centessa Pharmaceuticals' shares surged 48.11% in pre-market trading, reaching a 52-week high of $40.50.
Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals for $38.00 per share in cash, reflecting a strong endorsement of Centessa's promising drug pipeline. Additionally, shareholders will receive a contingent value right that could yield an extra $9.00 per share if certain milestones are met, raising the total potential value to $47.00 per share. This acquisition is expected to enhance the commercialization of Centessa's lead candidate, cleminorexton, which has shown best-in-class potential in clinical trials for narcolepsy.
The acquisition news has generated significant market optimism, driving Centessa's stock price to a new high as investors anticipate the benefits of the deal and the future of its drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTA
Wall Street analysts forecast CNTA stock price to fall
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.860
Low
27.00
Averages
38.75
High
62.00
Current: 39.860
Low
27.00
Averages
38.75
High
62.00
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating LiveRamp Holdings, Inc. (NYSE: RAMP) regarding its sale to Publicis Groupe at $38.50 per share, potentially infringing on shareholder rights.
- Merger Review: The merger between NextEra Energy, Inc. (NYSE: NEE) and Dominion Energy, Inc. will result in NextEra shareholders owning approximately 74.5% of the combined entity, prompting Halper Sadeh LLC to assess the transaction's compliance.
- Pharmaceutical Sale Inquiry: Centessa Pharmaceuticals plc (NASDAQ: CNTA) is being sold to Eli Lilly for $38.00 in cash per share plus up to $9.00 in contingent value rights, with Halper Sadeh LLC reviewing whether this transaction aligns with shareholder interests.
- Financial Transaction Scrutiny: Green Dot Corporation (NYSE: GDOT) is selling for $8.11 in cash and 0.2215 shares of a new publicly traded bank holding company, leading Halper Sadeh LLC to investigate if the terms restrict superior competing offers.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Insider Trading Investigation: Halper Sadeh LLC is investigating Select Medical Holdings Corporation's sale to a consortium led by its executives and directors for $16.50 per share in cash, which may infringe on shareholder rights.
- UniFirst Acquisition Details: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, potentially limiting superior competing offers.
- Centessa Pharmaceuticals Deal: Centessa Pharmaceuticals plc is selling to Eli Lilly for $38.00 in cash per share plus a non-transferable contingent value right that could yield up to $9.00 upon achieving certain milestones, prompting shareholders to consider their rights.
- Assertio Sale Dynamics: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash along with a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation: Halper Sadeh LLC is investigating Centessa Pharmaceuticals plc, Whitestone REIT, and Green Dot Corporation for potential violations of federal securities laws and breaches of fiduciary duties, which may expose shareholders to financial losses.
- Centessa Transaction Details: Centessa Pharmaceuticals is being sold to Eli Lilly for $38.00 per share in cash, plus a non-transferrable right worth up to $9.00, which could impact shareholder interests and future earnings.
- Whitestone REIT Sale: Whitestone REIT is being sold to Ares Management Corporation for $19.00 per share, and Halper Sadeh LLC may seek to increase the transaction price to ensure fair compensation for shareholders.
- Green Dot Transaction Structure: Green Dot Corporation's sale price includes $8.11 in cash and 0.2215 shares of a new publicly traded bank holding company for each share, with Halper Sadeh LLC representing shareholders to negotiate better terms and transparency.
See More
Eli Lilly's Dominance in Weight Loss Market
- Weight Loss Market Growth: Eli Lilly's anti-obesity drug Zepbound is experiencing rapid sales growth, which is expected to solidify the company's leadership in the fast-expanding weight loss market, especially with the recent launch of Foundayo that further broadens its addressable market.
- Diverse Product Portfolio: Beyond Zepbound, Eli Lilly boasts other drugs like Verzenio and Taltz, which generated $5.7 billion and $3.6 billion in sales last year, respectively, showcasing the company's strong growth potential in oncology and immunology, effectively mitigating competitive pressures.
- Strategic Acquisition Plans: Eli Lilly recently acquired Kelonia Therapeutics for $3.25 billion, enhancing its gene therapy platform expected to improve cancer treatment, while also expanding its neuroscience pipeline through the acquisition of Centessa Pharmaceuticals and deepening its oncology pipeline with Scorpion Therapeutics.
- Competitive Market Advantage: Compared to rival Novo Nordisk, Eli Lilly has a clear advantage in product diversity, allowing it to maintain its lead in the weight loss market, and despite facing competition from new drugs, it continues to drive long-term revenue growth.
See More
Eli Lilly's Leadership in the Weight Loss Market
- Weight Loss Market Growth: Eli Lilly's anti-obesity drug Zepbound is experiencing rapid sales growth, underscoring the company's leadership in the weight loss market, which is expected to drive overall revenue growth and enhance competitive positioning.
- Diverse Product Line: Eli Lilly achieved $5.7 billion in sales for its cancer treatment Verzenio, an 8% year-over-year increase, while immunosuppressant Taltz reached $3.6 billion, demonstrating its strong capabilities across multiple therapeutic areas that help mitigate market competition.
- Strategic Acquisition: Eli Lilly's acquisition of Kelonia Therapeutics for $3.25 billion grants access to an innovative gene therapy platform, expected to improve cancer treatment outcomes and further strengthen its competitive edge in genetic medicine.
- Future Growth Potential: Analysts expect Eli Lilly's new drugs Ebglyss, Jaypirca, and Kisunla to generate over $1 billion in annual sales, showcasing the company's ongoing innovation and growth potential across various fields.
See More
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
- Acquisition Activity: Eli Lilly accelerates its acquisition strategy in 2026 with the buyout of Ajax Therapeutics valued at up to $2.3 billion, including milestone payments, further solidifying its position in blood cancer treatments.
- Drug Development: Ajax's lead drug, AJ1-11095, is a next-generation JAK2 inhibitor currently in Phase 1 trials for patients with Myelofibrosis, aiming to expand treatment options for patients with rare blood cancers.
- Strategic Positioning: This marks Lilly's sixth acquisition this year, including a $6.3 billion deal for Centessa Pharmaceuticals focused on sleep disorders, demonstrating its commitment to deepening its oncology pipeline.
- Market Sentiment: Despite nearly a 20% decline in LLY shares in 2026, retail sentiment on Stocktwits remains bullish, indicating confidence in the company's acquisition strategy and its potential to enhance future growth.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating LiveRamp Holdings, Inc. (NYSE: RAMP) regarding its sale to Publicis Groupe at $38.50 per share, potentially infringing on shareholder rights.
- Merger Review: The merger between NextEra Energy, Inc. (NYSE: NEE) and Dominion Energy, Inc. will result in NextEra shareholders owning approximately 74.5% of the combined entity, prompting Halper Sadeh LLC to assess the transaction's compliance.
- Pharmaceutical Sale Inquiry: Centessa Pharmaceuticals plc (NASDAQ: CNTA) is being sold to Eli Lilly for $38.00 in cash per share plus up to $9.00 in contingent value rights, with Halper Sadeh LLC reviewing whether this transaction aligns with shareholder interests.
- Financial Transaction Scrutiny: Green Dot Corporation (NYSE: GDOT) is selling for $8.11 in cash and 0.2215 shares of a new publicly traded bank holding company, leading Halper Sadeh LLC to investigate if the terms restrict superior competing offers.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Insider Trading Investigation: Halper Sadeh LLC is investigating Select Medical Holdings Corporation's sale to a consortium led by its executives and directors for $16.50 per share in cash, which may infringe on shareholder rights.
- UniFirst Acquisition Details: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, potentially limiting superior competing offers.
- Centessa Pharmaceuticals Deal: Centessa Pharmaceuticals plc is selling to Eli Lilly for $38.00 in cash per share plus a non-transferable contingent value right that could yield up to $9.00 upon achieving certain milestones, prompting shareholders to consider their rights.
- Assertio Sale Dynamics: Assertio Holdings, Inc. is being sold to Garda Therapeutics for $18.00 per share in cash along with a contingent value right, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation: Halper Sadeh LLC is investigating Centessa Pharmaceuticals plc, Whitestone REIT, and Green Dot Corporation for potential violations of federal securities laws and breaches of fiduciary duties, which may expose shareholders to financial losses.
- Centessa Transaction Details: Centessa Pharmaceuticals is being sold to Eli Lilly for $38.00 per share in cash, plus a non-transferrable right worth up to $9.00, which could impact shareholder interests and future earnings.
- Whitestone REIT Sale: Whitestone REIT is being sold to Ares Management Corporation for $19.00 per share, and Halper Sadeh LLC may seek to increase the transaction price to ensure fair compensation for shareholders.
- Green Dot Transaction Structure: Green Dot Corporation's sale price includes $8.11 in cash and 0.2215 shares of a new publicly traded bank holding company for each share, with Halper Sadeh LLC representing shareholders to negotiate better terms and transparency.
See More
Eli Lilly's Dominance in Weight Loss Market
- Weight Loss Market Growth: Eli Lilly's anti-obesity drug Zepbound is experiencing rapid sales growth, which is expected to solidify the company's leadership in the fast-expanding weight loss market, especially with the recent launch of Foundayo that further broadens its addressable market.
- Diverse Product Portfolio: Beyond Zepbound, Eli Lilly boasts other drugs like Verzenio and Taltz, which generated $5.7 billion and $3.6 billion in sales last year, respectively, showcasing the company's strong growth potential in oncology and immunology, effectively mitigating competitive pressures.
- Strategic Acquisition Plans: Eli Lilly recently acquired Kelonia Therapeutics for $3.25 billion, enhancing its gene therapy platform expected to improve cancer treatment, while also expanding its neuroscience pipeline through the acquisition of Centessa Pharmaceuticals and deepening its oncology pipeline with Scorpion Therapeutics.
- Competitive Market Advantage: Compared to rival Novo Nordisk, Eli Lilly has a clear advantage in product diversity, allowing it to maintain its lead in the weight loss market, and despite facing competition from new drugs, it continues to drive long-term revenue growth.
See More
Eli Lilly's Leadership in the Weight Loss Market
- Weight Loss Market Growth: Eli Lilly's anti-obesity drug Zepbound is experiencing rapid sales growth, underscoring the company's leadership in the weight loss market, which is expected to drive overall revenue growth and enhance competitive positioning.
- Diverse Product Line: Eli Lilly achieved $5.7 billion in sales for its cancer treatment Verzenio, an 8% year-over-year increase, while immunosuppressant Taltz reached $3.6 billion, demonstrating its strong capabilities across multiple therapeutic areas that help mitigate market competition.
- Strategic Acquisition: Eli Lilly's acquisition of Kelonia Therapeutics for $3.25 billion grants access to an innovative gene therapy platform, expected to improve cancer treatment outcomes and further strengthen its competitive edge in genetic medicine.
- Future Growth Potential: Analysts expect Eli Lilly's new drugs Ebglyss, Jaypirca, and Kisunla to generate over $1 billion in annual sales, showcasing the company's ongoing innovation and growth potential across various fields.
See More
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
- Acquisition Activity: Eli Lilly accelerates its acquisition strategy in 2026 with the buyout of Ajax Therapeutics valued at up to $2.3 billion, including milestone payments, further solidifying its position in blood cancer treatments.
- Drug Development: Ajax's lead drug, AJ1-11095, is a next-generation JAK2 inhibitor currently in Phase 1 trials for patients with Myelofibrosis, aiming to expand treatment options for patients with rare blood cancers.
- Strategic Positioning: This marks Lilly's sixth acquisition this year, including a $6.3 billion deal for Centessa Pharmaceuticals focused on sleep disorders, demonstrating its commitment to deepening its oncology pipeline.
- Market Sentiment: Despite nearly a 20% decline in LLY shares in 2026, retail sentiment on Stocktwits remains bullish, indicating confidence in the company's acquisition strategy and its potential to enhance future growth.
See More
